Profusa Rolls Out Healthcare Research Version Of Lumee Tissue Oxygen Monitoring

Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces the launch of its Healthcare Research version of the Lumee tissue oxygen monitoring into the contract research organizations (CRO) market. This strategic step is expected to generate immediate service-based revenue .

This initiative targets a high-growth segment of the pharmaceutical services industry, where demand is accelerating for more predictive, real-time biological data to improve drug development efficiency and decision-making.   Profusa's Lumee tissue oxygen products are commercially ready and available for immediate deployment, which will allow CRO partners to rapidly incorporate the technology into existing study designs and offer differentiated services to their clients with minimal implementation risk.

The CRO and pharmaceutical services market continues to experience strong growth, driven by increasing R&D investment, regulatory momentum around new approach methodologies (NAMs), and the need to reduce late-stage development risk. Industry forecasts estimate the global pharmaceutical CRO market could expand from approximately $47.9 billion in 2025 to over $91.2 billion by 2034 at a CAGR of more than 7%, underscoring the expanding addressable opportunity for advanced biosensing platforms.